Visually cued fear conditioning test for memory impairment related to cortical function.


Journal

Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700

Informations de publication

Date de publication:
12 2020
Historique:
received: 18 07 2020
revised: 26 08 2020
accepted: 15 09 2020
pubmed: 23 10 2020
medline: 8 9 2021
entrez: 22 10 2020
Statut: ppublish

Résumé

Fear conditioning tests are intended to elucidate a subject's ability to associate a conditioned stimulus with an aversive, unconditioned stimulus, such as footshock. Among these tests, a paradigm related to precise cortical functions would be increasingly important in drug screening for disorders such as schizophrenia and dementia. Therefore, we established a new fear conditioning paradigm using a visual cue in mice. In addition, the validity of the test was evaluated using a genetically engineered mouse, heterozygous deficient in Mdga1 (Mdga1+/-), which is related to schizophrenia. Mice were given footshocks associated with a visual cue of moving gratings at training in 25-minute sessions. The mice showed the conditioned response of freezing behavior to the visual stimulus at testing 24 hours after the footshocks. In the test for validation, the Mdga1+/- deficient mice showed significantly less freezing than wild-type mice. The visually cued fear conditioning paradigm with moving gratings has been established, which is experimentally useful to evaluate animal cortical functions. The validity of the test was confirmed for Mdga1-deficient mice with possible deficiency in cortical functions.

Identifiants

pubmed: 33089673
doi: 10.1002/npr2.12146
pmc: PMC7722643
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

371-375

Informations de copyright

© 2020 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of NeuropsychoPharmacology.

Références

Neurosci Lett. 2020 Jan 18;716:134677
pubmed: 31812551
J Neurosci. 2008 Jul 23;28(30):7492-500
pubmed: 18650327
Nat Protoc. 2006;1(3):1306-11
pubmed: 17406415
Dev Dyn. 2011 Jan;240(1):96-107
pubmed: 21104742
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):336-41
pubmed: 23248271
Vision Res. 1999 Sep;39(18):3071-81
pubmed: 10664805
Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1089-100
pubmed: 18384059
Eur J Neurosci. 2012 Sep;36(6):2801-11
pubmed: 22738127
Science. 2018 Jun 22;360(6395):1349-1354
pubmed: 29930137
Learn Mem. 2004 Nov-Dec;11(6):686-96
pubmed: 15576886
J Vis Exp. 2014 Mar 01;(85):
pubmed: 24637495
Neuropsychopharmacol Rep. 2020 Dec;40(4):371-375
pubmed: 33089673
Science. 2014 Jun 6;344(6188):1173-8
pubmed: 24904169
Cell Rep. 2017 Dec 26;21(13):3637-3645
pubmed: 29281813
Brain Cogn. 2015 Apr;95:54-61
pubmed: 25682352

Auteurs

Kazuya Kuboyama (K)

Department of Neuropharmacology, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki city, Kagawa, Japan.

Yuki Shirakawa (Y)

Department of Neuropharmacology, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki city, Kagawa, Japan.

Koji Kawada (K)

Department of Neuropharmacology, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki city, Kagawa, Japan.

Naoki Fujii (N)

Department of Neuropharmacology, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki city, Kagawa, Japan.

Daiki Ojima (D)

Department of Molecular Neurobiology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan.

Yasushi Kishimoto (Y)

Department of Biophysics, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki city, Kagawa, Japan.

Tohru Yamamoto (T)

Department of Molecular Neurobiology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan.

Maki K Yamada (MK)

Department of Neuropharmacology, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki city, Kagawa, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH